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Abstract
Introduction: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human malignancies and constitutes approximately 
1.6–5% of the malignant neoplasms of the thyroid gland. ATC usually manifests itself with the local symptoms due to a rapidly enlarging 
thyroid mass, and as other thyroid cancers, has only seldom been reported to cause thyrotoxicosis. Up to now only 9 cases of ATC with 
concomitant thyrotoxicosis have been described.
Case report: We report a rare case of a 66-year-old woman, who had had the preexisting large, euthyroid multinodular goiter for almost 50 
years. She was consulted by a doctor because of a 4-week history of thyrotoxicosis, symptoms of the congestive heart failure and a rapid 
increase in the size of the goiter. Thyroid hormone levels were consistent with a hyperthyroid state. The fine-needle aspiration biopsy 
confirmed a diagnosis of the anaplastic thyroid carcinoma, the small cells variant. The 99m Tc-pertechnetate scintigraphy visualized non-
homogenous tracer distribution with hot nodules.
 She was given a doxorubicin (20 mg/week) and required the continuous antithyroid treatment. The patient died a one year after the first 
symptoms of the disease occurred. 
Discussion: The association between ATC and a thyrotoxic state is very rare. In most cases, thyrotoxicosis concomitant with ATC was 
thought to be a result of the destruction of the thyroid follicles by the rapid infiltration with malignant cells, resulting in the leakage of 
preformed hormones to the circulation. In that case the most probable cause of thyrotoxicosis was the multinodular goiter coexisting 
with ATC. A simultaneous onset of tumor growth, thyrotoxicosis and a relatively long survival time of our patient is worth to notice and 
discuss. (Endokrynol Pol 2018; 69 (1): 28–31)
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Streszczenie
Wstęp: Anaplastyczny rak tarczycy (ATC) jest jednym z najagresywniejszych nowotworów w patologii ludzkiej i stanowi około 1,6–5% 
złośliwych nowotworów tarczycy. Rozpoczyna się zwykle objawami miejscowymi wtórnymi do szybkiego wzrostu guza i, podobnie 
jak w przypadków innych typów raka tarczycy, jedynie sporadycznie jest on skojarzony z nadczynnością tarczycy. Dotychczas opisano 
9 przypadków ATC ze współistniejącą tyreotoksykozą.
Opis przypadku: Autorzy prezentują rzadki przypadek 66-letniej kobiety ze stwierdzanym od blisko 50 lat ogromnym wolem guzowa-
tym, wcześniej w stanie eutyreozy. Pacjentka zgłosiła się do lekarza z powodu utrzymujących się od 4 tygodni objawów nadczynności 
tarczycy, zastoinowej niewydolności krążenia oraz gwałtownego wzrostu objętości wola. Wyniki badań hormonalnych były typowe dla 
pierwotnej nadczynności tarczycy. W biopsji cienkoigłowej potwierdzono rozpoznanie raka anaplastycznego z małych komórek. Scynty-
grafia technetowa wykazała niejednorodne gromadzenie znacznika oraz kilka gorących guzków. Pacjentka była leczona doksorubicyną 
w dawce 20 mg/tydzień, wymagała także stałego podawania tyreostatyku. Zmarła po roku od wystąpienia pierwszych objawów choroby. 
Dyskusja: Skojarzenie ATC z tyreotoksykozą jest niezwykle rzadkie. W większości przypadków nadczynność tarczycy współistniejąca 
z ATC wynika z uwalniania do krążenia hormonów z nabłonka tarczycy niszczonego przez naciek nowotworowy. W prezentowanym 
przypadku najbardziej prawdopodobną przyczyną nadczynności tarczycy było współistnienie wola guzowatego toksycznego. Warto 
zwrócić uwagę na jednoczesne wystąpienie gwałtownego wzrostu wola i tyreotoksykozy oraz na względnie długie przeżycie pacjentki. 
(Endokrynol Pol 2018; 69 (1): 28–31)
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Introduction
Anaplastic thyroid carcinoma (ATC) derives from the 
well-differentiated thyroid follicular epithelial cells 
and in different geographical regions constitutes ap-
proximately from 1.3% to 9.8% of all thyroid malignant 
neoplasms [1]. It is one of the most aggressive human 
malignancies, with a total disease-specific mortality of 
at least 90% [2]. ATC usually manifests itself with the 
local symptoms due to a rapidly enlarging thyroid mass 
and, as other thyroid cancers, has only seldom been 
reported to cause thyrotoxicosis.
Case report
We report a case of a 66-year-old woman, who had had 
the preexisting large, euthyroid multinodular goiter for 
almost 50 years. She contacted a doctor with a history of 
4-week of unintentional 10 kg weight loss, palpitations, 
dyspnoea, shortness of breath, insomnia, tremor and 
a rapid increase in the size of the goiter. Physical exami-
nation revealed a large, firm, nontender multinodular 
goiter. There were some bilaterally palpable lymph 
nodes in the angles of mandible regions. Her heart 
rate was totally irregular, 120 beats per minute, blood 
pressure was 150/80 mm Hg. She had bilateral ankle 
oedema. No signs of orbitopathy were present and she 
did not have any symptoms suggesting an airway com-
pression. Thyroid hormone levels were consistent with 
a hyperthyroid state and were as follows: suppressed 
serum level of thyrotropin (TSH) < 0.005 uIU/ml, free 
thyroxine (fT4) = 64.2 pmol/l (range 10–20 pmol/l) and 
free triiodothyronine (fT3) = 14.3 pmol/l (range 3.1–6.5 
pmol/l). ECG revealed atrial fibrillation. At that moment, 
the patient firmly refused hospitalization and extending 
the diagnostic tests with biopsy for family reasons. The 
thyrotoxicosis was treated with thiamazole in a daily 
dose of 60 mg and a beta-blocker (bisoprolol 10 mg/day). 
Hydrochlorothiazide (in the dose of 12.5 mg/day) and 
acenocoumarol were also administered.
Within two weeks of the treatment, patient’s gen-
eral condition much improved. Moreover palpitation, 
tremor and oedema disappeared. The heart rate was 
80 per minute, but the atrial fibrillation was still record-
ed. Thyroid function tests revealed the following: fT4 = 
34.2 pmol/ml, anti-thyroid peroxidase antibodies (anti-
TPO) = 0.11 IU/ml (range 0–100 IU/ml), thyroglobulin 
= 120 ng/ml (range 0–60 ng/ml), anti-thyroglobulin an-
tibodies = 28 IU/ml (standard < 40 IU/ml), thyrotropin 
receptor antibody (TRAb) = 0.8 IU/l (range 0.0–1.5 IU/l). 
Carcinoembryonic antigen, alpha-fetoprotein levels 
and other tumor markers (CA-125, CA 19-9, CA 15-3) 
were in the normal levels. The dose of thiamazole was 
consistently reduced to a maintenance dose, 5 mg per 
day. The euthyroidism was achieved following 8 weeks 
of antithyroid drugs therapy. Repeated thyroid function 
test showed: fT4 = 18.5 pmol/l, fT3 = 7.3 pmol/l. After 
the next 3 months of treatment, the goiter had become 
more firm and the patient started to complain about 
choking sensations. At that moment she agreed to be 
hospitalized and she was referred to the Department 
of Endocrinology, Diabetes and Isotope Therapy to 
undergo more advanced examinations because of the 
suspicion of ATC. 
The thyroid ultrasound examination revealed 
a large mass with a heterogeneous echogenicity, which 
extended below the sternum, especially on the left side. 
There were multiple focal lesions in the thyroid gland 
with a hypoechogenic and hypervascular structure 
in the left lobe. The chest X-ray picture showed an 
enlargement of the superior mediastinum, a deviation 
of trachea to the right with its constriction and bilat-
eral metastatic lesions in the lungs. ECG confirmed 
a persistent atrial fibrillation with a ventricular mean 
rate 78/min. The 99m Tc-pertechnetate scintigraphy 
visualized a non-homogenous tracer distribution with 
a high uptake within the hyperfunctioning nodules 
(hot nodules) (Figure 1). A thyroid radioiodine uptake 
was 16% after 24 hours.
A fine-needle aspiration biopsy of the thyroid con-
firmed the diagnosis of anaplastic thyroid carcinoma, 
the small cells type with a positive thyroglobulin reac-
tion (Figure 2).
The tumor was considered unresectable because of its 
advanced stage and the presence of lung metastases. Due 
Figure 1. Thyroid 99mTc-pertechnetate scintigraphy: foci with 
excessive accumulation of the tracer
Rycina 1. Scyntygrafia tarczycy 99mTc z widocznymi ogniskami 
wzmożonego wychwytu znacznika
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to the rise of fT4 to 23 pmol/l after the antithyroid medica-
tion withdrawal, the continuous treatment with thiama-
zole was restored in a dose of 10 mg and kept till the end 
of the follow-up (Figure 3). The patient had a treatment 
of chemotherapy based on doxorubicin (20 mg/week) and 
she died a year after the first medical consultation.
Discussion
Anaplastic carcinoma of the thyroid is one of the most 
aggressive cancers, with a median survival time re-
ported from 1.2 to 10 months after the diagnosis [3]. 
It is worth noting, that although this type of cancer is 
a rare neoplasm, the mortality rate is above 90% and it is 
the cause of 14–39% deaths of patients with the thyroid 
cancer [4]. One-year and 5-year relative survival rates 
are estimated to be 10–20% and 4.6–5.4% respectively 
[3, 5]. All patients diagnosed with ATC are classified as 
stage IV according to the American Joint Committee on 
Cancer TNM system [6]. 
The clinical manifestation of ATC reflects the local 
invasion and mass effect caused by the thyroid tumor 
growth. Nearly all patients have the symptoms of an 
enlarging primary tumor of the neck and dysphagia. 
Moreover, also a change of voice or stridor occurs [5]. 
However, the history of our patient’s illness was dif-
ferent. The symptoms of thyrotoxicosis and the heart 
failure were the reasons to seek a medical attention. She 
initially refused to be hospitalized and that decision 
caused a delay in the diagnosis.
The association between ATC and a thyrotoxic state 
is very rare. To our knowledge, only nine other cases 
have been described in the literature [7–15].
The rapid growth of the primary tumor may rarely 
cause a nonspecific thyroiditis with symptoms of thyro-
toxicosis. One of the possibilities of that state is the fol-
licular disruption and a release of the thyroid hormones 
from the preformed pool. Phillips et al. suggested that 
the thyroid hormones level may be elevated due to 
an alternative mechanism, one of the hypothesis is 
a hormone production from metastases [12, 16]. Howev-
er, in that case the unusual symptoms of the disease was 
probably caused by the multinodular goiter coexisting 
with ATC. Low concentration of the TSH-receptor bind-
ing antibodies and the anti-TPO antibodies excluded 
the Graves’ disease or an autoimmune thyroiditis as 
potential causes of the thyrotoxicosis. It should be 
noted that active thyroid nodules were seen in the 
scintigraphy, even after several weeks of the antithy-
roid treatment. Moreover, we observe the recurrence 
of the hyperthyroidism during the short break in the 
thiamazole therapy. It is also relevant that this treatment 
was very effective to control symptoms of the conges-
tive heart failure and it was necessary to continue the 
therapy within the whole period of the follow-up. In 
the literature, we found only one case report of a patient 
who had ATC and coexisting thyrotoxicosis most likely 
caused by the multinodular goiter [9].
Various prognostic factors, such as age, gender, 
size of the tumor and the presence of the metastases 
are considered as important in a prognosis of patients’ 
outcome. Due to the rare occurrence of the ATC and its 
fast, aggressive course, there are not many randomized 
trials with an assessment how that factors determine 
the survival. 
Kebebew et al. analyzed data from the SEER da-
tabase and they estimated that the age under 60 and 
the intrathyroidal ATC location are the two main 
factors for expecting longer survival [4]. Our patient 
was a 66-year-old woman and there have been found 
metastases in the lungs, what indicated a poor progno-
Figure 2. FNA thyroid biopsy: anaplastic carcinoma of small cells 
with positive stainig of thyroglobulin (×200)
Rycina 2. BAC tarczycy. Rak anaplastyczny z małych komórek z 
dodatnią reakcja na tyreoglobulinę (×200)
Figure 3. Thyroid function during the treatment: transient post 
thiamasole hipothyroidism and relapse of hyperthyroidism after 
discontinuation of the medication
Rycina 3. Funkcja tarczycy w trakcie leczenia: przejściowa 
polekowa niedoczynność i nawrót nadczynności tarczycy po 
zaprzestaniu leczenia
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sis. On the other hand, she lived longer than median 
survival of anaplastic cancer patients. It is also worth 
to emphasize and discuss a simultaneous onset of tu-
mor growth and thyrotoxicosis with a relatively long 
survival time in the presented case report. Because it is 
an extremely rare state, there is no data in the literature 
comparing the influence of the hyperthyroidism to 
the better outcome in the ATC. The longer survival of 
our patient due to the presence of the multinodular 
goiter is only one of the possible hypothesis. Also in 
the literature there are studies suggesting that thyroid 
disease co-morbid with ATC may have an influence 
on the outcome [4, 17].
The standards of the ATC treatment have not 
been established yet. There are only few options and 
unfortunately, the survival benefits are still limited. 
Multidisciplinary therapy, including neoplasm resec-
tion, radiotherapy and chemotherapy, may prolong 
the survival in some groups of patients; a better prog-
nosis is expected for patients without tumor residues 
(R0) [2, 5]. In chemotherapy, doxorubicin is the most 
common drug, but the response rate is estimated to be 
only about 22%. To improve the outcome, clinical trials 
were conducted, in which drug combinations, such as 
doxorubicin, cisplatin and taxanes or docetaxel and 
cisplatin were used, but the response rate was about 
50%. What is more, there are a few new drugs tested 
for the ATC treatment. One of them is sorafenib, ap-
proved by the FDA for patients with the metastatic 
thyroid cancer, however it has a limited efficacy in the 
anaplastic carcinoma [18].
Summarizing, the anaplastic thyroid carcinoma is 
a rare type of the neoplasm, but it is associated with 
high mortality. It usually occurs with a normal level of 
thyroid hormones and only a few cases of ATC with 
a concomitant thyrotoxicosis have been reported. In 
most cases thyrotoxicosis was caused by the hormones 
released from the destroyed follicles, but in our patient 
it was most likely secondary to the presence of the 
multinodular goiter.
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